[February 11, 2005]

Biophan Noted in BusinessWeek Report on Nanotechnology Science and Marketplace; Company Named Among Key Players in Healthcare Sector

ROCHESTER, N.Y. --(Business Wire)-- Feb. 11, 2005 -- Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, has announced that the Company has been included in BusinessWeek magazine's (February 14, 2005 issue, page 67) cover story about the latest innovations in nanotechnology, the multi-billion-dollar marketplaces nanoscience currently enable, and the potential for significant further growth.

The BusinessWeek cover story, entitled "The Business of Nanotech," describes the progression of nanotechnology from the laboratories to a burgeoning marketplace involving key industries, including healthcare, automotive, energy, computers and semiconductors, advanced consumer materials, and many others.

In the BusinessWeek article, Biophan is listed as one of seven nanotechnology players in the healthcare sector along with General Electric, Johnson & Johnson, NASA, and others.

The article quotes nanotechnology market researchers who project the 2005 nanotechnology marketplace will reach an estimated $13 billion. By the end of the decade, however, the nanotechnology market will grow to an estimated $292 billion, according to the industry observers.

"The BusinessWeek article does an excellent job of describing the scope and potential of the nanotechnology marketplace and the position of technology leaders such as Biophan in enabling the nanotechnology revolution," said Michael Weiner, Biophan CEO. "The article conveys the financial and investment potential that nanotechnology presents in healthcare and medical science, where Biophan holds key proprietary technologies."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin-film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses, or applications. This total includes 30 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

[ Back To TMCnet.com's Homepage ]

Discussions: